A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma

Purpose of Study:

1) To learn the response rate [complete response (CR), partial response (PR)] of Rituximab in combination with Denileukin diftitox in previously untreated patients with advanced stage (3 or 4) CD20+ B-cell follicular grade 1 and 2 non-Hodgkin lymphoma (NHL).

2) To assess the overall survival, time-to-progression, duration of response, and time-to-therapy of these patients after treatment with Rituximab in combination with Denileukin diftitox.

3) To determine whether treatment with Rituximab in combination with Denileukin diftitox depletes or inhibits the function of Treg cells in patients with untreated Follicular grade 1 and 2 B-cell NHL.

Schema: Reg
Rituximab
Denileukin